Navigation Links
Everest Data on Short- and Long-Term Use of Otsuka's,Investigational Novel Treatment, Tolvaptan, Published in Journal of,the American Medical Association and Featured in ACC's Late,Breaking Clinical Trials

of tolvaptan.

In each short-term study, significantly more patients in the tolvaptan groups reported improvements in dyspnea (difficult breathing) on the first inpatient day compared with the placebo groups (p less than 0.001 in both study A and study B). Significantly more patients in the tolvaptan group had improvements in investigator-assessed pedal edema at inpatient day seven or discharge in study B (p equal to 0.020), while the difference between groups in study A did not reach statistical significance (p equal to 0.070).(1)

Long-Term Trial: Pre-Specified Secondary Endpoints

The secondary endpoints of the composite of cardiovascular death or cardiovascular hospitalization, the incidence of cardiovascular mortality, and the incidence of clinical worsening of heart failure did not differ between the two treatment groups. A larger number of cardiovascular hospitalizations were adjudicated as due to myocardial infarction in the placebo group (n equal to 42) than in the tolvaptan group (n equal to 25) and a larger number were adjudicated as due to stroke in the tolvaptan group (n equal to 45) than in the placebo group (n equal to 24).(2)

The long-term tolvaptan data were consistent with those reported in the short-term clinical studies. Specifically, long-term tolvaptan treatment significantly reduced participants' body weight at day one (p less than 0.001) compared to placebo and the difference in body weight numerically favored tolvaptan through week 56. The long-term trial also documented that tolvaptan patients who enrolled with hyponatremia (serum sodium less than 134 mEq/L) exhibited significantly greater corrections in serum sodium at day seven or discharge, if earlier, (p less than 0.001) and the effect was maintained through 40 weeks of treatment.(2)

"The EVEREST data suggest that the mechanism of action of tolvaptan may represent a new therapeutic strategy that could provide symptomatic improvement for short-term care of
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
2. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
3. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
4. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
5. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
6. Surfaxin (Lucinactant) Long-Term Survival Advantage vs. Comparators Published in Pediatrics
7. Long-Term Extension of Ulcerative Colitis Study Shows Remicade Responders Maintained Improvement Through Two Years of Follow-Up
8. New Long-Term Data Analyses for Bifeprunox Show Favorable Effects Versus Placebo in Stabilized Patients with Schizophrenia
9. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
10. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
11. UCB Presents Long-Term CImzia Data in Crohns Disease

Post Your Comments:
(Date:11/6/2009)...ba, Nov. 6 With his proposed healt... his sights on cutting name-brand prescription dru...ll into the "Part D" coverage gap, universally kno...the potential cost-cutting and feel it,s a promisi...st powerful lobbyists want a revised program that ...
(Date:11/6/2009)...E PARK, N.C., Nov. 6 Chimerix, Inc...ailable antiviral therapeutics to address life-thr...pment of the company,s lead antiviral compound, CM...he Global Health Security Initiative (GHSI). CMX0...oped for the treatment of smallpox, as well as oth...
(Date:11/6/2009)...6 NexBio Inc., in collaboration wi...nd Prevention (CDC), St. Louis University, and the...ication of two articles in the peer-reviewed journ...that DAS181 (Fludase ® ) may play a potential... of the Pandemic Influenza A(H1N1) and drug-resist...
Breaking Medicine Technology:Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 2Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 3Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4New Surgery Institute at Children 26apos 3Bs National Medical Center Aims to Improve Surgery and Eliminate Pain 57400 1New Surgery Institute at Children 26apos 3Bs National Medical Center Aims to Improve Surgery and Eliminate Pain 57400 2New Surgery Institute at Children 26apos 3Bs National Medical Center Aims to Improve Surgery and Eliminate Pain 57400 3New Surgery Institute at Children 26apos 3Bs National Medical Center Aims to Improve Surgery and Eliminate Pain 57400 4Pennsylvania Patient Safety Authority Releases September Advisory 57396 1Pennsylvania Patient Safety Authority Releases September Advisory 57396 2Pennsylvania Patient Safety Authority Releases September Advisory 57396 3Pennsylvania Patient Safety Authority Releases September Advisory 57396 4Pennsylvania Patient Safety Authority Releases September Advisory 57396 5livethesource 28TM 29 Hosts Company Launch Event While Supporting The Brent Shapiro Foundations Annual Sober Night Out 57392 1livethesource 28TM 29 Hosts Company Launch Event While Supporting The Brent Shapiro Foundations Annual Sober Night Out 57392 2livethesource 28TM 29 Hosts Company Launch Event While Supporting The Brent Shapiro Foundations Annual Sober Night Out 57392 3
...ings from an Otsuka Pharmaceutical Co, Ltd. Sponso...sociation Annual Meeting -, SAN DIEGO, May 23, 200...ts (13- 17 years old) with schizophrenia, the Otsu...bb Company atypical,antipsychotic aripiprazole dem...ebo on the primary efficacy endpoint, Positive and...
...eren (Zurich), Switzerland, May 24, 2007 - Cytos,B...from a,placebo-controlled, double-blind combined p...e candidate for the treatment of,psoriasis and oth...a first-time-in-man clinical trial and included 48... psoriasis. In a first part,of the study, the safe...
Other Medicine Technology:Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 2Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 3Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 4Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 5Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 6Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 7Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 8Investigational Study Evaluates the Effectiveness of Aripiprazole,in Adolescents With Schizophrenia 9Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 2Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 3Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for,the Treatment of Psoriasis 4
(Date:11/8/2009)...are Reform Bill ,, Critical legislation would...ricans ,, HARRISBURG, Penn., Nov. 8 /PRNewswir...United States House of Representatives passed crit...engthen Medicare for seniors and end discriminatio...mericans out of affordable health coverage. ,...
(Date:11/8/2009)...th holds open house at Victoria campus , ...009 -- UCW Academy of Health invites anyone lookin...alth care industry to attend their open house in V...cademy of Health, which offers diplomas in areas s..., designs its programs to meet the needs of the he...
(Date:11/8/2009)...tion,s Job Creators ,, WASHINGTON, Nov. 8 /PRNe...ssage of the health care bill (H.R. 3962), Small B...l) president & CEO Karen Kerrigan issued the f... voting for H.R. 3962 voted to burden our nation,s... and penalties. Even in the best of economic times...
(Date:11/8/2009)...re/ -- Tonight the House of Representatives passed...ark health reform legislation that will ensure eve...ble and secure health care coverage. The legislati...ustry,s worst practices, would extend coverage to ...illion over ten years. Groups representing doctors...
(Date:11/8/2009)... is pleased to announce that it has been successfu...und who recently received an award on the $800 mil...cludes not only the Veterans Administration, but a...encies. , New York, NY (P...leased to announce that it has been successful in ...
Breaking Medicine News(10 mins):Health News:AARP Pennsylvania Key Vote News Alert 2Health News:AARP Pennsylvania Key Vote News Alert 3Health News:AARP Pennsylvania Key Vote News Alert 4Health News:College Invites Public to Explore Career Options in Health Care 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 2Health News:Democratic National Committee Chairman Tim Kaine Issues Statement Praising the House of Representative's Historic Vote to Pass Health Insurance Reform 3Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3
...moking pot and cigar of the 70s. If you want to ki...just stay on your cell phone and check your e-mail... A study commissioned by Hewlett-Packard shows ...ducted by scientists from the Institute of Psychia...
...n Russia was spread by infected migratory birds. ...se province for the past three months, and earlier...oving towards European countries. Earlier reports ... the outbreak in Russia and Kazakhstan are caused ...
...ke of folic acid during the first trimester of the...es with low birth weight than anyone else. Researc...ad found that increased levels of folic acid or fo...rns and published their results in the recent edit...
...y many for latest and quick medical treatment .A B...n, Elliot Knott to India for treatment after disco...on in the NHS. The decision to seek treatme...nd from an ice-skating injury, then face a further...
...p people with severe asthma according to a recent ...tween decreased intake of antioxidants such as vit...onducted to examine the intakes and blood concentr... a particularly low intake of antioxidants. The bl...
...ces with unhealthy foods could be used to treat// ...e University of California, Irvine, and her collea...after eating strawberry ice cream as a child. ...res that suggested they had had an unpleasant expe...
Other Medicine News:Health News:E-Mail Affects Brain More Than Marijuana 2Health News:Bird flu infection spreads from Asia to Europe 2Health News:Study Links Folic Acid With Increased Birth Weight 2Health News:Indian Hospitals – A Destination For Quality Medical Care 2Health News:Unpleasant Memory of Food could Be Used to Treat Obesity 2
Sugita Aneurysm Clip Bent (M)
Sugita Aneurysm Clip Bent (S)
Sugita Aneurysm Clip J-Shaped (M)
Sugita Aneurysm Clip 1/4 Cvd.
Medicine Products: